GDP Theatre Seminars

Highlighting how Environmental Sustainability is considered in the Pharmaceutical and Health Care Supply Chain whilst maintaining a high standard of service, without compromising compliance. Will also discuss how the transport sector, and more specifically the Pharmaceutical and Healthcare transport sector, must be practical in their approach to Environmental Sustainability as well as also the consideration of the financial implications. This will also highlight that “Going Green” isn’t JUST about which type of fuel you may be using, but also the collaborative efforts that can, and are, undertaken by all the links in the Supply Chain.

Two billion people globally live without access to essential medicines. Healthcare companies want to do more to support communities but can be put off by the labour-intensive processes involved and the compliance risks posed.

Introducing, Boaz, a SaaS product that bridges the gap between healthcare companies and NGOs. Boaz makes managing the complexities of the product donation process easier to deliver more healthcare products to more people in need.

During its 20-year history to date, IHP has distributed medicines to 100 million people. Through Boaz, IHP invites pharmaceutical industry leaders to exponentially increase the scale of medical aid distribution, globally.

Alan will provide an update on developments at the GDP-Universal Compliance Initiative and outline its plans for pharma-logistics to come together to pursue a decarbonisation program in pursuit of it's net-zero commitments.

In the pharmaceutical industry, outdated technology and fragmented systems have resulted in disjointed processes and increased potential for errors. Particularly in batch review and release, disparate systems hinder efficient data-exchange, leading to delays and inefficiencies.

This presentation highlights the need for integrated solutions to enable end-to-end traceability, emphasising the importance of breaking down silos and fostering cross-functional collaboration. We advocate for the adoption of emerging AI-based technologies to automate these processes, outlining their potential to streamline QA reviews, reduce regulatory risks, and deliver tangible benefits to organisations, fostering a more efficient and reliable industry. Case studies will be presented to illustrate this transformative impact.

• Overview of supply chain challenges
• Supply chain management and impact on QP’s & RPi’s
• Case study
• Key learnings

Presentation on the supply chain giving a visual demonstration and talk of each of the points. Each point will highlight the risks involved and possible mitigations. We will include elements of temperature management packaging and how this can aid successful distribution, as well as the different carrier options available.

20 minutes will be spent interacting with the audience. We will show an FMEA model example of a pharmaceutical export route and ask members of the audience to volunteer the risk identificationa and scores and how this can be mitigated. This will then conclude in a completed lane validation and the audience will have an understanding of how to complete.

• Temperature monitoring and how to handle temperature excursions in the supply chain.
• Ensuring correct storage of medicines, end-to-end from manufacturer to patient.
• Management and calibration of temperature equipment.
• Temperature mapping of warehouses, cold stores and cold-chain vehicles.

In this presentation, I will aim to explore the challenges and benefits associated with using a 3PL provider and choosing the right one. I then will explore the journey of the change from in-house warehousing to a 3PL. My discussion will span various considerations, from selecting the appropriate 3PL to the preparation and actual transition process, along with the impact on GDP in these areas. Drawing from practical observations, both the advantages and challenges will be discussed.

The Government of the United Kingdom (UK) introduced temporary measures to address problems with the supply of medicines to Northern Ireland in the wake of the UK’s withdrawal from the European Union (EU); both the UK and EU recognised that there were difficulties in operating the “Protocol on Ireland and Northern Ireland”, an agreement intended to protect the terms of the 1998 “Belfast Agreement” and preserve the close relationship between the Republic of Ireland and Northern Ireland.

These temporary measures (such as the Northern Ireland MHRA Authorised Route, “NIMAR”) were considered necessary by the UK, as the implementation of the Protocol on Ireland and Northern Ireland had created supply chain issues which impacted on public health in the region.

Despite these temporary measures, there was evidence that supply problems persisted – this was seen not only for medicines, but other areas of trade between Great Britain and Northern Ireland as well.

On 27 February 2023, the UK and EU published the “Windsor Political Declaration by the European Commission and the Government of the United Kingdom”, which is also known as the “Windsor Framework”. This framework, which was adopted by the EU-UK Joint Committee in March 2023, applies to trade between Great Britain and Northern Ireland whilst aiming to protect the EU market. This presentation will summarise the framework and MHRA expectations for the licensing & supply of medicines across the UK going forward.

When considering the installation of a temperature controlled storage facility for pharmaceutical products, whatever the URS specification, or basis of supply (capital outlay, rental, lease arrangement etc),

What are the 5 basic skills a potential supplier must tick to support you and your company?

During our presentation, I will cover off in more detail the 5 points above and point you in the right direction for a successful supply of a pharmaceutical temperature controlled environment.